和元生物
(688238)
| 流通市值：42.02亿 | | | 总市值：42.12亿 |
| 流通股本：6.47亿 | | | 总股本：6.49亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 206,512,365.05 | 121,787,253.4 | 50,540,466.83 | 267,696,887.26 |
| 营业收入 | 206,512,365.05 | 121,787,253.4 | 50,540,466.83 | 267,696,887.26 |
| 二、营业总成本 | 354,168,220.96 | 222,762,303.94 | 105,516,677.95 | 492,112,471.65 |
| 营业成本 | 212,055,843.52 | 131,393,467.67 | 62,592,849.59 | 306,570,027.86 |
| 税金及附加 | 5,611,105.77 | 3,775,523.55 | 1,813,444.84 | 7,258,937.61 |
| 销售费用 | 38,525,773.5 | 24,678,333.71 | 11,896,392.06 | 49,416,488.51 |
| 管理费用 | 55,588,573.24 | 36,667,674.81 | 18,417,716.99 | 73,927,674.81 |
| 研发费用 | 37,517,424.02 | 24,940,632.96 | 11,972,398.08 | 48,745,854.25 |
| 财务费用 | 4,869,500.91 | 1,306,671.24 | -1,176,123.61 | 6,193,488.61 |
| 其中:利息费用 | 8,770,907.19 | 5,173,939.61 | 2,652,555.78 | 8,614,681.24 |
| 其中:利息收入 | 4,023,649.26 | 3,950,496.53 | 3,889,841.06 | 2,516,710.62 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 286,734.12 | 248,450.39 | 218,826.4 | 86,487.4 |
| 加:投资收益 | -1,147,101.63 | -806,043.2 | -419,975.07 | 6,089,808.86 |
| 资产处置收益 | -176,222.05 | - | - | -1,072,763.43 |
| 资产减值损失(新) | -1,369,120.67 | -1,737,710.45 | -485,610.76 | -22,903,467.32 |
| 信用减值损失(新) | -3,257,379.44 | -2,693,577.61 | -45,905.36 | -2,506,747.67 |
| 其他收益 | 6,835,952.7 | 4,800,788.73 | 2,468,784.44 | 11,964,839.62 |
| 四、营业利润 | -146,482,992.88 | -101,163,142.68 | -53,240,091.47 | -232,757,426.93 |
| 加:营业外收入 | 5,204.63 | 202.68 | 201.48 | 50,004.27 |
| 减:营业外支出 | 51,780.26 | 21,780.26 | - | 372,419.99 |
| 五、利润总额 | -146,529,568.51 | -101,184,720.26 | -53,239,889.99 | -233,079,842.65 |
| 减:所得税费用 | -167,050.51 | 374,355.48 | -175,536.31 | 1,730,170.02 |
| 六、净利润 | -146,362,518 | -101,559,075.74 | -53,064,353.68 | -234,810,012.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -146,362,518 | -101,559,075.74 | -53,064,353.68 | -234,810,012.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -146,106,665.19 | -101,414,070.19 | -53,084,824.41 | -235,062,409.94 |
| 少数股东损益 | -255,852.81 | -145,005.55 | 20,470.73 | 252,397.27 |
| 扣除非经常损益后的净利润 | -147,857,432.9 | -103,113,016.51 | -54,012,240.42 | -246,409,397.67 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.23 | -0.16 | -0.08 | -0.37 |
| (二)稀释每股收益 | -0.23 | -0.16 | -0.08 | -0.37 |
| 八、其他综合收益 | -186,030.56 | -145,308.44 | -90,380.13 | 2,026,920.04 |
| 归属于母公司股东的其他综合收益 | -186,030.56 | -145,308.44 | -90,380.13 | 2,026,920.04 |
| 九、综合收益总额 | -146,548,548.56 | -101,704,384.18 | -53,154,733.81 | -232,783,092.63 |
| 归属于母公司股东的综合收益总额 | -146,292,695.75 | -101,559,378.63 | -53,175,204.54 | -233,035,489.9 |
| 归属于少数股东的综合收益总额 | -255,852.81 | -145,005.55 | 20,470.73 | 252,397.27 |
| 公告日期 | 2026-10-29 | 2026-08-25 | 2026-04-28 | 2026-04-21 |
| 审计意见(境内) | | | | 标准无保留意见 |